Marvin Reyes, MD
Infectious Disease · Fountain Valley, CANPI 1356378160
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $108 of the $136 with a category attached, or 79.1%. GSK accounts for 75.9% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for infectious disease clinicians in CA, where the typical reported total is $297.
Across 3 payments — averaging $45.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$103
- Johnson & Johnson$28
- Biomerieux Inc$4
What the payments were for
- Food & beverage$10879%
- Education$2821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $103 |
| Johnson & Johnson | 1 | $28 |
| Biomerieux Inc | 1 | $4 |
How this compares
$136 in reported general payments places this provider in the 35th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 68 | $296,467 |
| TivicayDolutegravir Sodium | 12 | $24,606 |
| ErtapenemErtapenem Sodium | 31 | $13,136 |
| Lopinavir-RitonavirLopinavir/Ritonavir | 13 | $9,757 |
| Vancomycin Hcl | 67 | $8,453 |
| Daptomycin | 18 | $6,857 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 35 | $5,842 |
| Meropenem | 19 | $4,079 |
| Cefepime Hcl | 20 | $2,621 |
| CeftriaxoneCeftriaxone Sodium | 34 | $2,338 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 27 | $2,075 |
| Efavirenz | 13 | $1,564 |
| Cefazolin Sodium | 18 | $702 |
| Rifampin | 17 | $655 |
| Ethambutol Hcl | 23 | $605 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Fountain Valley
- Sujata Lalla-ReddyFountain Valley$57K
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.